← Leaderboards
Jessica R. Allegretti
Brigham And Women'S Hospital
$3,079,283
Attributed
$4,701,551
Total exposure
4
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $801.6K · FY2018–25$1M$750K$500K$250K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,701,551 · 4
By mechanism
R01$2,836,210 · 1
K23$983,290 · 1
T32$473,725 · 1
R21$408,326 · 1
Top collaborators
- Scott B Snapper7 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Lisa L Strate$4,638,836
- David A. Hafler$48,350,086
- Murugaiyan Gopal$7,662,393
- Raymond J Peterson$6,571,498
- Dolores Corella$490,387
Others in their field
Other Emerging Leaders on “Inflammatory Bowel Diseases”
- Gary Fanger · Rise Therapeutics, Llc$6,265,549
- Ta-Chiang Liu · Washington University$5,779,180
- Gretchen E Diehl · Utah State Higher Education System--University Of Utah$5,221,167
- Chun-Jun Guo · Weill Medical Coll Of Cornell Univ$4,652,677
- Yang-Yu Liu · Brigham And Women'S Hospital$4,496,450
- Hasan Zaki · Ut Southwestern Medical Center$4,090,040
Research focus
Inflammatory Bowel DiseasesSignal TransductionS DiseasePreventRefractoryCytotoxic T-LymphocytesCsf3 GeneDesignClinical TrialsClinical ResearchAnti-CancerChronicAdoptive TransferBiologicalDisease ManagementCancer TherapyBostonAldesleukinAffinityCd4 Positive T LymphocytesChargeCell TypeCellsChronic Disease
Grant awards (14)
Research Training in Gastrointestinal and Hepatic Diseases$372,956
T32 · FY2025 · DK · contact PI
Research Training in Gastrointestinal and Hepatic Diseases$100,769
T32 · FY2025 · DK · contact PI
Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of CrohnâÂÂs Disease$583,336
R01 · FY2024 · DK
Understanding Clostridium difficile Infection in Patients with inflammatory Bowel Disease$196,358
K23 · FY2024 · DK · contact PI
Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of CrohnâÂÂs Disease$543,883
R01 · FY2023 · DK
Understanding Clostridium difficile Infection in Patients with inflammatory Bowel Disease$196,358
K23 · FY2023 · DK · contact PI
Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of Crohn's Disease$551,543
R01 · FY2022 · DK
Understanding Clostridium difficile Infection in Patients with inflammatory Bowel Disease$196,358
K23 · FY2022 · DK · contact PI
Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of CrohnâÂÂs Disease$553,742
R01 · FY2021 · DK
Understanding Clostridium difficile Infection in Patients with inflammatory Bowel Disease$196,358
K23 · FY2021 · DK · contact PI
Low Dose Interleukin-2 for Regulatory T cell Modulation and the Treatment of CrohnâÂÂs Disease$603,706
R01 · FY2020 · DK
Understanding Clostridium difficile Infection in Patients with inflammatory Bowel Disease$197,858
K23 · FY2020 · DK · contact PI
Low dose interleukin 2 for the expansion of regulatory T cells and the treatment of moderate to severe ulcerative colitis$172,413
R21 · FY2019 · DK
Low dose interleukin 2 for the expansion of regulatory T cells and the treatment of moderate to severe ulcerative colitis$235,913
R21 · FY2018 · DK